Treatment with PCSK9 inhibitors in patients with chronic kidney disease at very high cardiovascular risk

Nefrologia (Engl Ed). 2023 Dec:43 Suppl 2:133-135. doi: 10.1016/j.nefroe.2024.01.015. Epub 2024 Jan 30.

Affiliations

¹ Nephrology Department, Hospital Universitario Puerta del Mar, Cádiz, Spain.
² Hospital Pharmacy Department, Hospital Universitario Puerta del Mar, Cádiz, Spain.
³ Nephrology Department, Hospital Universitario Puerta del Mar, Cádiz, Spain. Electronic address: [email protected].

PMID: 38296719
DOI: 10.1016/j.nefroe.2024.01.015

No abstract available

Publication types

Letter

MeSH terms

Cardiovascular Diseases* / etiology
Cardiovascular Diseases* / prevention & control
Heart Disease Risk Factors
Humans
PCSK9 Inhibitors
Proprotein Convertase 9
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / drug therapy
Risk Factors

Substances

PCSK9 Inhibitors
PCSK9 protein, human
Proprotein Convertase 9